IV Fosphenytoin for TN

What patients should know about the 2026 Neurology study on acute trigeminal neuralgia?

Quick answer

Clinicians have studied IV fosphenytoin for acute trigeminal neuralgia as a hospital-based intravenous treatment for severe TN exacerbations. It is not a routine tablet. No patient should treat it as a home painkiller or try to obtain it outside specialist clinical care.

In 2026, Neurology published a multicentre, randomised, double-blind, placebo-controlled trial called “IV Fosphenytoin for Acute Trigeminal Neuralgia”. Researchers reported Class I evidence that IV fosphenytoin reduced pain intensity more than placebo 120 minutes after the first dose in patients with acute TN exacerbations.

Patients should read this finding with care. The study gives clinicians stronger evidence to consider when TN pain becomes severe and unmanageable. It does not show that fosphenytoin suits everyone, that every hospital offers it, or that it replaces established UK treatment guidance.

What is fosphenytoin?

Hospital and neurological teams mainly use fosphenytoin in specialist settings. The body converts fosphenytoin into phenytoin after administration. Phenytoin belongs to a group of medicines often known as anti-seizure or anticonvulsant medicines.

Phenytoin also acts on sodium channels. That helps explain why clinicians have looked at its possible role in severe neuralgic pain crises.

Even so, fosphenytoin is not a standard TN treatment. It requires clinical assessment, monitoring and judgement about whether it is safe for the individual patient.

The 2026 study

The 2026 Neurology trial examined IV fosphenytoin in people experiencing acute trigeminal neuralgia exacerbations. These severe flare periods can increase pain intensity and attack frequency so sharply that ordinary oral medication may not give enough short-term control.

Researchers designed the trial as multicentre, randomised, double-blind and placebo-controlled. In plain English, the study compared IV fosphenytoin with placebo while reducing bias in how clinicians gave treatment and assessed pain.

The primary outcome focused on pain reduction from baseline to 120 minutes after the first dose. At that time point, IV fosphenytoin performed better than placebo.

This result has clinical importance, but clinicians must interpret it carefully. The study looked at short-term acute pain relief. It did not prove long-term disease control. Nor did it establish a universal treatment pathway for everyone with facial pain.

What did it test?

The trial tested IV fosphenytoin as a rapid hospital-based rescue or bridging treatment for acute TN exacerbations. Clinicians assessed and treated patients in a clinical setting.

A medicine given through a vein in hospital differs completely from a tablet prescribed for daily use. Clinical teams must monitor blood pressure, heart rate and respiratory function during IV fosphenytoin treatment.

Doctors also need to review medical history, current medicines, cardiac risk, liver or kidney problems, pregnancy, allergies and the patient’s overall condition.

Patients should not stop, reduce or change their prescribed medication because of this study. They should not seek fosphenytoin outside proper medical care.

Why this matters

Trigeminal neuralgia causes sudden, severe, electric shock-like facial pain. The International Classification of Headache Disorders describes TN as recurrent, brief, electric shock-like pain in the trigeminal nerve distribution, often triggered by innocuous stimuli.

For patients, ordinary actions may trigger attacks. Speaking, eating, drinking, brushing teeth, washing the face or feeling wind on the skin can become frightening.

Severe flares can disable people. Some patients cannot eat or drink properly. Others cannot speak, sleep, wash or leave home. Fear of the next shock can take over daily life.

Many patients still describe a familiar and unacceptable pattern: dentistry, general practice, emergency departments, neurology and pain services, but no clear acute plan.

Modern neurological care should not accept that.

Long-term management remains essential. However, it does not always answer the immediate crisis question: what should happen when a person with TN has severe acute pain today?

The 2026 study helps because it focuses on that gap.

UK treatment context

In the UK, carbamazepine remains central to standard trigeminal neuralgia treatment. NHS information describes carbamazepine as the only medicine currently licensed to treat trigeminal neuralgia in the UK.

If carbamazepine fails, causes unacceptable side effects or becomes unsuitable, specialists may consider other medicines. These can include oxcarbazepine, lamotrigine, gabapentin, pregabalin or baclofen. Some patients also need neurosurgical review or pain specialist input.

IV fosphenytoin belongs in a different category. It does not sit alongside routine long-term TN medication. The 2026 study examined acute exacerbations, where clinicians may consider hospital-based rescue or bridging treatment.

Clinicians should regard IV fosphenytoin in UK TN care as a specialist hospital treatment consideration for acute exacerbations, not as a licensed routine medicine for trigeminal neuralgia.

A patient should not ask, “Can I have fosphenytoin instead of my usual treatment?”

The better question is, “If my trigeminal neuralgia becomes unmanageable, what is my acute escalation plan?”

What not to assume

No patient information article about IV fosphenytoin for acute trigeminal neuralgia should create false hope.

This study does not prove that fosphenytoin suits every person with facial pain. It does not remove the need for accurate diagnosis. NHS guidance, NICE CKS guidance and specialist assessment still matter. The trial also does not mean every UK hospital has an acute TN pathway using IV fosphenytoin.

Fosphenytoin carries recognised risks. Intravenous treatment can affect blood pressure, heart rhythm and breathing. Patients may also experience drowsiness, dizziness, nausea, low blood pressure or other reactions. Serious reactions remain uncommon, but they carry real clinical importance, especially for patients with cardiac risk or complex medical histories.

This caution protects patients. The study provides evidence for clinicians to consider, not a treatment plan for patients to follow alone.

Painkillers and TN

Many patients with severe TN receive standard painkillers during a crisis. This can feel deeply frustrating because trigeminal neuralgia does not behave like ordinary pain.

Standard painkillers such as paracetamol usually do not control trigeminal neuralgia pain. NHS information explains that clinicians use anticonvulsant medicines because they act on nerve signalling rather than general pain pathways.

Patients should not read this as a reason to refuse pain relief in urgent care. Instead, it shows why acute TN needs informed clinical assessment, not a generic pain response.

Urgent care teams should assess whether the symptoms fit trigeminal neuralgia, whether red flags suggest another diagnosis, whether medicine toxicity or withdrawal may play a role, and whether the patient needs urgent neurology or pain advice.

What now?

At TNA UK, we regularly hear from people who feel abandoned during acute trigeminal neuralgia crises.

Some patients report that professionals have described their pain as dental, stress-related or anxiety-based, even when symptoms fit TN. Others have no written plan for what to do when pain becomes unmanageable.

Can modern neurology do better?

Acute trigeminal neuralgia deserves recognition as a serious neurological pain presentation. Patients need informed assessment, timely escalation and clear referral routes. Clinicians need better education because many will rarely see TN in practice.

Aneeta Prem said:

“People living with trigeminal neuralgia should not be left to endure acute pain crises without a clear plan. This study is not a simple answer, and it is not a treatment patients can arrange for themselves. It does, however, strengthen the case for better emergency pathways, stronger professional education and serious recognition of acute facial pain.”

The 2026 Neurology study should not shrink into one drug name. Its wider value lies in the clinical question it raises: what should happen when someone with trigeminal neuralgia has severe acute pain and ordinary treatment does not control it?

General practice, emergency care, neurology, pain medicine and commissioning all need to answer that question.

Questions to ask

Patients may find it helpful to ask their GP, neurologist, pain specialist or emergency care team:

Could this be an acute trigeminal neuralgia exacerbation?

Does my diagnosis fit classical TN, idiopathic TN, secondary TN or another facial pain condition?

What should I do if my pain becomes unmanageable?

Do I have a written acute flare plan?

At what point should I seek urgent help?

Does my local hospital have an acute TN pathway?

Which hospital-based rescue options exist for severe TN flares?

Should a clinician refer me to neurology, pain medicine or neurosurgery?

Could any of my current medicines cause side effects, interactions or toxicity?

These questions do not challenge clinicians. They help patients make sure severe facial pain receives proper assessment and does not get dismissed.

Urgent help

Anyone with severe, escalating or unmanageable pain should seek medical advice.

NHS 111 can advise on urgent care routes. Call 999 or attend emergency care if there is immediate danger, new neurological symptoms, collapse, confusion, a severe medication reaction, suicidal thoughts, inability to eat or drink safely, or if you cannot keep yourself safe.

No one should have to carry unbearable pain alone.

TNA UK cannot diagnose, prescribe or replace clinical care. Our role is to support, inform and help people feel less isolated while they seek appropriate medical help.

What it means

The 2026 Neurology study gives clinicians an important evidence-based discussion point for acute trigeminal neuralgia exacerbations.

It also validates what patients have said for years: acute TN pain can become a crisis, and services need better answers.

Larger studies, clearer emergency pathways, UK-specific clinical protocols and stronger professional education would all help. One study does not solve the problem. It does, however, move the conversation away from endurance and towards properly planned care.

People living with trigeminal neuralgia deserve more than sympathy. They deserve recognition, timely treatment and a health system that understands the severity of acute facial pain.

TNA UK support

TNA UK supports people living with trigeminal neuralgia and facial pain through information, helpline support, e-helpline support, Regional Support Groups, webinars, events, patient voice work and awareness.

Trained volunteer staff run our helpline. Many understand the condition personally. They cannot diagnose, prescribe or replace medical care, but they can offer emotional support, practical information and signposting.

Freephone helpline: 0800 999 1899
E-helpline: [email protected]
Website: www.tna.org.uk